The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Abstract
Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that sensitivity of cancer cells to MCL-1 inhibition is inversely related to BCL-XL expression level and the capacity for BCL-XL to neutralize pro-apoptotic BH3 proteins such as BIM60,61.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [60]
In the citing paper
“Conversely, the BCL2 inhibitor venetoclax is currently available for the treatment of CLL patients who fail to obtain clinical benefit from conventional therapies [1046], and several other molecules with a similar mechanism of action are currently in clinical development [118] (source https://clinicaltrials.gov/).”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [118]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
MOLREP : an Automated Program for Molecular Replacement
Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930
Self-citationChen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,001
Deng, Y., Li, C., Huang, L. J., Xiong, P., Li, Y., Liu, Y., Li, S., Chen, W., Yin, Q., Li, Y., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1535 · Cited by 8
Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells
Duan, L., Tadi, M. J., O’Hara, K. M., & Maki, C. G. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107375 · Cited by 8
Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors
Liang, X., Li, X., Zhao, Z., Nie, Y., Yao, Z., Ren, W., Yang, X., Hou, X., & Fang, H. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105643 · Cited by 8
Parkhurst, A. N., Wang, S. Z., Findlay, T., Malebranche, K. J., Odabas, A., Alt, J., Maxwell, M. J., Kaur, H., Peer, C. J., Figg, W. D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04868-9 · Cited by 8
Aksoy, O., Lind, J., Sunder-Plassmann, V., Vallet, S., & Podar, K. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156062 · Cited by 8
Petit, A., Garcia, C., Bueren‐Calabuig, J. A., Vuillard, L. M., Ferry, G., & Boutin, J. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001123 · Cited by 8
Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Yi, X., Jain, N., Iles, L. R., Ayres, M., Wierda, W. G., & Gandhi, V. V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.833714 · Cited by 8
Signal Propagation Within the MCL-1/BIM Protein Complex
Heckmeier, P. J., Ruf, J., Buhrke, D., Janković, B. G., & Hamm, P. M. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167499 · Cited by 10
Fultang, N., Schwab, A. M., McAneny-Droz, S., Grego, A., Rodgers, S., Vidal, B., Heiser, D., Scherle, P., & Bhagwat, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1343004 · Cited by 7
Yu, M., Nah, G. S. S., Krishnan, V., Sulaimi, F. N., Ng, K. P., Wang, C., Bhatt, S., Chuah, C. T. H., Bergstrom, D. E., & Ong, S. T. (2024) · Leukemia · doi:10.1038/s41375-024-02418-0 · Cited by 7
Zhang, L., Wei, Y., Luo, M., Ren, S.-Y., Zhan, X., Wang, C., Li, Z., Zhu, R., Yan, S., Cheng, Y., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07481-8 · Cited by 7
Self-citationJiménez‐Vacas, J. M., Westaby, D., Figueiredo, I., Brandon, A. D. H., Padilha, A., Yuan, W., Seed, G., Bogdan, D., Gürel, B., Bertan, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64042-5 · Cited by 7
MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis
Gui, W., Páral, P., Dhamija, B., Hagag, E., Dusa, M., Humajová, J., Francová, P., Kučka, J., Pankrác, J., Schütz, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66831-4 · Cited by 7
Beltrán‐Visiedo, M., Jiménez‐Alduán, N., Díez, R., Cuenca, M., Benedi, A., del Valle, A. S., Azaceta, G., Palomera, L., Peperzak, V., Anel, A., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13522 · Cited by 7
Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors
Peng, Z., Gillissen, B. F., Richter, A., Sinnberg, T. W., Schlaak, M. S., & Eberle, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063453 · Cited by 7
Yang, Y., Ahmad, E., Premkumar, V., Liu, A., Rahman, S. A., & Nikolovska‐Coleska, Z. (2024) · Protein Science · doi:10.1002/pro.5019 · Cited by 7
Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells
Krastinaite, I., Charkavliuk, S., Navakauskienė, R., & Borutinskaite, V. V. (2024) · Genes · doi:10.3390/genes15050648 · Cited by 7
Martín, F., Alcon, C., Marín, E., Morales-Sánchez, P., Manzano-Muñoz, A., Díaz, S., García, M. L. P., Samitier, J., Lu, A., Villanueva, A., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07513-3 · Cited by 8
Pethő, B., Vangel, D., Csenki, J. T., Zwillinger, M., & Novàk, Z. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob01146j · Cited by 7
Xie, K., Liu, Z., Chen, N., & Chen, T. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.06.014 · Cited by 7
MCL1 as putative target in pancreatoblastoma
Reißig, T. M., Uhrig, S., Jost, P. J., Luchini, C., Vicentini, C., Liffers, S., Allgäuer, M., Adsay, V. N., Scarpa, A., Lawlor, R. T., et al. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03349-w · Cited by 7
Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies
Leśniak, M., Lipniarska, J., Majka, P., Lejman, M., & Zawitkowska, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316708 · Cited by 7
Ookura, M., Fujii, T., Yagi, H., Ogawa, T., Kishi, S., Hosono, N., Shigemi, H., Yamauchi, T., Ueda, T., & Yoshida, A. (2017) · Oncotarget · doi:10.18632/oncotarget.22871 · Cited by 7
Methods to Probe Conformational Activation and Mitochondrial Activity of Proapoptotic BAK
Singh, G., & Moldoveanu, T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8861-7_13 · Cited by 7
Liu, F., Knight, T. E., Su, Y., Edwards, H. J., Wang, G., Wang, Y., Taub, J. W., Lin, H., Sun, L., & Ge, Y. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00638-4 · Cited by 7
Emerging pathways for precision medicine in management of cholangiocarcinoma
Rahnemai‐Azar, A. A., Abbasi, A., Acher, A. W., Weber, S. M., & Pawlik, T. M. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.08.008 · Cited by 7
BECN1 modulates hematopoietic stem cells by targeting Caspase-3-GSDME-mediated pyroptosis
Yang, X., Ge, L., & Wang, J. (2020) · Blood Science · doi:10.1097/bs9.0000000000000051 · Cited by 7
Deng, M., Hu, J., Tong, R., Guo, H., & Liu, Y. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10245 · Cited by 7
BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia
Brumatti, G., Kaloni, D., de Castro, F. A., & Amarante-Mendes, G. P. (2023) · Biochemical Journal · doi:10.1042/bcj20210608 · Cited by 8
Potts, M. A., Mizutani, S.-Y., Deng, Y., Vaidyanathan, S., Ting, K. E., Giner, G., Sridhar, S., Shenoy, G., Liao, Y., Diepstraten, S. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62615-y · Cited by 6
Self-citationShin, H., Dorrity, T. J., Aruda, J., Wiegand, K. A., Nam, J. S., Yang, J., Jones, A. S., Gertie, J. A., Singh, M. K., Yin, Y., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117026 · Cited by 6
Leukemic stem cells as drivers of therapeutic resistance in acute myeloid leukemia
Silva, S. L. R., Barbosa, G. A. D. C., Rios, J. V. B., & Bezerra, D. P. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119295 · Cited by 6
Apoptotic signaling pathways in bone metastatic lung cancer: a comprehensive analysis
Zhang, Y., Zheng, Y., Zhang, J., Xu, C., & Wu, J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01151-5 · Cited by 6
Zhang, X., Tao, Y., Xu, Z., Jiang, B., Yang, X., Huang, T., & Tan, W. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116542 · Cited by 6
The function and mechanism of clinical trial agent CPI-613 in multiple myeloma
Wang, H., Zhang, Y., Xiang, R., Xiang, R., Gong, H., Gong, Y., Xu, H., Ma, Z., Xie, Y., Hu, B., et al. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116717 · Cited by 6
Chemical dissection of selective myeloid leukemia-1 inhibitors: How they were found and evolved
Wang, L., Chen, Y., Zhang, M., Liu, J., Li, H., Li, W., Wu, S., Zhang, Y., Li, W., & Wang, B. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117168 · Cited by 7
Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations
Koolivand, Z., Bahreini, F., Rayzan, E., & Rezaei, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41355 · Cited by 6
König, C., Ivanisenko, N. V., Иванисенко, В. А., Kulms, D., & Lavrik, I. N. (2025) · Communications Biology · doi:10.1038/s42003-024-07409-6 · Cited by 6
Farrokhnazar, E., Moghbelinejad, S., Najafipour, R., & Teimoori‐Toolabi, L. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41933 · Cited by 6
Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis
Payne, N. L., Pang, S. H. M., Freeman, A. J., Ozkocak, D. C., Limar, J. W., Wallis, G., Zheng, D., Mendonca, S., O’Reilly, L. A., Gray, D. H. D., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02412-0 · Cited by 7
Bourafai-Aziez, A., Sebban, M., Benabderrahmane, M. B., Marekha, B., Denis, C., Paysant, H., Weiswald, L., Carlier, L., Bureau, R., Coadou, G., et al. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1680434 · Cited by 6
Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling
Surman, D. R., Xu, Y., Lee, M.-J., Trepel, J. B., Brown, K., Ramineni, M., Splawn, T. G., Diggs, L. P., Hodges, H. C., Davis, J. L., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0887 · Cited by 6
Seipel, K., Brügger, Y., Mandhair, H. K., Bacher, U., & Pabst, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012587 · Cited by 6
Molica, M., & Perrone, S. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2140137 · Cited by 6
Jia, J., Li, M., Li, Y., Xiao, J., & Dai, H. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09804-x · Cited by 7
Enabling, Decagram-Scale Synthesis of Macrocyclic MCL-1 Inhibitor ABBV-467
Brady, P., Sorensen, B. K., Risi, R. M., Curtin, M. L., Mantei, R. A., Florjancic, A. S., Mastracchio, A., Ji, C., Kunzer, A. R., Lai, C., et al. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c00939 · Cited by 6
Discovery and optimization of (2-naphthylthio)acetic acid derivative as selective Bfl-1 inhibitor
Niu, P., Xu, H., & Fan, M. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129658 · Cited by 6
Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma
Vernooij, L., Kamili, A., Ober, K., van Arkel, J., Lankhorst, L. H., Vermeulen, E., Al-Khakany, H., Tax, G., van den Boogaard, M. L., Fletcher, J. I., et al. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100168 · Cited by 6
Unleashing Blocked Apoptosis in Cancer Cells: New MCL1 Inhibitors Find Their Groove
Leber, B. F., Kale, J., & Andrews, D. W. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1167 · Cited by 6
Cuenca, M., van Nieuwenhuijzen, N., Moesbergen, L. M., Bloem, A. C., Minnema, M. C., & Peperzak, V. (2021) · Haematologica · doi:10.3324/haematol.2021.279517 · Cited by 6
Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis
Potts, M. A., Mizutani, S., Garnham, A. L., Suen, C. S. N. L. W., Kueh, A. J., Tai, L., Pál, M., Strasser, A., & Herold, M. J. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01145-w · Cited by 6
Self-citationCombined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma
Glinkina, K., Teunisse, A. F. A. S., Gelmi, M. C., de Vries, J., Jager, M. J., & Jochemsen, A. G. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000911 · Cited by 6
Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells
Chen, L. S., Keating, M. J., Wierda, W. G., & Gandhi, V. V. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1622098 · Cited by 6
de Souza, S. M., de Souza, L. S., Silva, V. R., Soares, M. B. P., Bezerra, D. P., Góis, R. W. D. S., da Silva, H. C., Santiago, G. M. P., & Militão, G. C. G. (2022) · Planta Medica · doi:10.1055/a-1910-5776 · Cited by 6
Gong, J., Djajawi, T. M., Moujalled, D. M., Pomilio, G., Khong, T. T., Zhang, L., Fedele, P. L., Low, M. S. Y., Anderson, M. A., Riffkin, C. D., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01487-7 · Cited by 5
Self-citationSarac, B., Yücer, S., Çiftçi, F., Ghorbanpour, M., & Özerol, E. A. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03864-2 · Cited by 5
Rutter, S. F., Kang, T., Ryan, G. F., Shi, B., Vella, C. L., Rajasekhar, P., Cutter, S. W., Hodge, A. L., Ozkocak, D. C., Ang, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64206-3 · Cited by 5
Platelet aging and desialylation increase apoptotic priming and BCL-XL dependence
Grozovsky, R., Fraser, C. S., Qin, X., Spetz, J. K. E., & Sarosiek, K. A. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08205-8 · Cited by 5
IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics
Ming, Z., Lim, S. Y., Stewart, A., Pedersen, B., Shklovskaya, E., Menzies, A. M., Carlino, M. S., Kefford, R. F., Lee, J., Scolyer, R. A., et al. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.01.017 · Cited by 5
Hartman, M. L., Koziej, P., Kluszczyńska, K., & Czyż, M. (2023) · Cancers · doi:10.3390/cancers15194799 · Cited by 5
Wichert, M. C., Fortner, C., Niedermayer, A., Bender, J., Enzenmüller, S., Debatin, K., Meyer, L. H., & Seyfried, F. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013194 · Cited by 5
Bacterial effector OspB hijacks apoptosis through peptide-bond recombination of BH3 domain proteins
Shao, Y., Yang, D., Gao, X., Wang, M., Meng, L., Niu, T., Li, X., Ding, J., Shao, F., & Xu, Y. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.09.018 · Cited by 5
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
Dart, C. R., Mukherjee, N., Amato, C. M., Goulding, A., MacBeth, M. L., Gulick, R. J. V., Couts, K. L., Lambert, J. R., Norris, D. A., Robinson, W. A., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080749 · Cited by 5
Erdogdu, U., Dolgikh, N., Laszig, S., Särchen, V., Meister, M. T., Wanior, M., Knapp, S., & Boedicker, C. (2021) · Neoplasia · doi:10.1016/j.neo.2021.11.012 · Cited by 5
Séguy, L., Daressy, F., Lahlil, S., Corvaisier, S., Dumontet, V., Litaudon, M., Apel, C., Roussi, F., Wiels, J., Robert, A., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122433 · Cited by 6
Al‐Odat, O. S., Elbezanti, W. O., Gowda, K., Srivastava, S. K., Amin, S., Jonnalagadda, S. C., Budak-Alpdoǧan, T., & Pandey, M. K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1436786 · Cited by 5
Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy
Chaudhary, B., Arya, P., Sharma, V., Kumar, P., Singla, D., & Grewal, A. S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108388 · Cited by 5
Jaya, I., Safriadi, F., Wijaya, I., Pitaloka, P., Afifah, E., Medina, F. S., & Bashari, M. H. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104895 · Cited by 5
Mycobacterium tuberculosis: prePPARing and Maintaining the Replicative Niche
Stutz, M. D., & Pellegrini, M. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.08.001 · Cited by 5
Uncovering Human Mixed Lineage Kinase Domain-Like Activation in Necroptosis
Guibao, C. D., Petrinjak, K., & Moldoveanu, T. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0229 · Cited by 5
The Effect of Core Replacement on S64315, a Selective MCL-1 Inhibitor, and Its Analogues
Sipos, S., Bálint, B., Szabó, Z. B., Ondi, L., Csékei, M., Szlávik, Z., Proszenyák, Á., Murray, J. B., Davidson, J. E. P., Chen, I., et al. (2021) · ACS Omega · doi:10.1021/acsomega.1c02595 · Cited by 5
Self-citationSaxena, K., Dinardo, C. D., Daver, N. G., & Konopleva, M. Y. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(20)30464-x · Cited by 5
New drugs for new targets in lymphoma
Younes, A. (2019) · Hematological Oncology · doi:10.1002/hon.2592 · Cited by 5
Anti-apoptotic capacity of Mcl-1Δ127
Wang, Y., Su, W., Mai, Z., Si, Y., Wang, X., & Chen, T. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.181 · Cited by 5
SOHO State of the Art Updates and Next Questions: Harnessing Apoptosis in AML
Saxena, K., Dinardo, C. D., Daver, N. G., & Konopleva, M. Y. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.08.015 · Cited by 5
Mantle cell lymphoma: insights into therapeutic targets at the preclinical level
Klener, P. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1813718 · Cited by 5
Fan, Y., Hou, X., & Fang, H. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200916124641 · Cited by 5
Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors
Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114526 · Cited by 5
A genome-wide CRISPR screen identifies HuR as a regulator of apoptosis induced by dsRNA and virus
Gao, H., Lin, Y., Huang, C., Li, X., Diamond, M., Liu, C., Zhang, R., & Zhang, P. (2022) · Journal of Cell Science · doi:10.1242/jcs.258855 · Cited by 5
Tolksdorf, B., Zarif, S., Eberle, J., Hazini, A., Dieringer, B., Jönsson, F., Kreppel, F., Kurreck, J., & Fechner, H. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02081-3 · Cited by 5
Minority MOMP: a toxic, slow demise
Xu, Y., Surman, D. R., & Ripley, R. T. (2020) · Oncotarget · doi:10.18632/oncotarget.27753 · Cited by 5
Targeting Adaptation to Cancer Treatment by Drug CombinationsPreprint
Wang, H., Luna, A., Yan, G., Li, X., Babur, Ö., Mills, G. B., Sander, C., & Korkut, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.14.439861 · Cited by 5
Multiplex design and discovery of proximity handles for programmable proteome editingPreprint
Suiter, C. C., Ahn, G., Chiu, M., Fu, Y., Sadre, S., Simon, J. J., Lee, D. S., Fowler, D. M., Maly, D. J., Baker, D. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.13.681693 · Cited by 5
A multitier virtual screening study of phytoconstituents as Myeloid Cell Leukemias 1 inhibitors
Liu, W., Khalid, M., Wahab, S., Siddiqui, M. F., Khan, S. H., Sadiq, M., & Khatoon, Z. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2226739 · Cited by 4
Mi, W., van Tienderen, G. S., Shi, S., Broeders, A., Monfils, K., Roest, H. P., van der Laan, L. J. W., & Verstegen, M. M. A. (2025) · International Journal of Cancer · doi:10.1002/ijc.35483 · Cited by 4
Mansour, M. A., El-Salamoni, M. A.-F., & Mostafa, H. N. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100975 · Cited by 4
Lefebvre, C. C., Giowachini, P., Derrien, J., Naour, M., Corre, I., Thirouard, L., Douillard, E., Chiron, D., Guillonneau, F., Treps, L., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07920-6 · Cited by 4
Saad, J. J., Newman, R., Khabusheva, E., Aakko, S., Durand, E., Tambe, M., Kuusanmäki, H. A., Parsons, A., Miettinen, J. J., Javarappa, K. K., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70130 · Cited by 4
PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models
Valentini, E., Gentile, G., Martile, M. D., D’Aguanno, S., Brignone, M., Stefano, A. M. D., Caprio, M. D., Melucci, E., Botti, C., Pelle, F., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03635-w · Cited by 4
Han, Q., Jiang, S., Chen, J., & Xue, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1742651 · Cited by 4
Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies
Stafylidis, C., & Diamantopoulos, P. T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062171 · Cited by 4
Yue, J., Li, Y., Li, F., Zhang, P., Li, Y., Xu, J., Zhang, Q., ZHANG, C., He, X. D., Wang, Y., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106350 · Cited by 4
HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Seipel, K., Kohler, S., Bacher, U., & Pabst, T. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090443 · Cited by 4
Molecular docking analysis of MCL-1 inhibitors for breast cancer management
Alam, Q. (2023) · Bioinformation · doi:10.6026/97320630019707 · Cited by 4
Seipel, K., Mandhair, H. K., Bacher, U., & Pabst, T. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040184 · Cited by 4
Modeling the Binding of Anticancer Peptides and Mcl-1
Alhammadi, S. H. A., Baby, B., Antony, P., Jobe, A., Humaid, R. S. M., Alhammadi, F. J. A., & Vijayan, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126529 · Cited by 4
Vier, J., Häcker, G. A., & Kirschnek, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07064-z · Cited by 4
Emerging concepts in drug discovery for cancer therapy
Murga, M., & Fernández-Capetillo, Ó. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13325 · Cited by 4
Lance, A. L., Chiad, Z., Seegers, S. L., Paschall, S., Drummond, K., Steuerwald, N., Yang, H., Chen, J., Voorhees, P. M., Avalos, B. R., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27420 · Cited by 4
A Joint Odyssey into Cancer Genetics
Cory, S., & Adams, J. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055543 · Cited by 4
Metadata
- Authors
- Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., Bruno, A., Csekei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyak, A., Balint, B., Ondi, L., Blasko, G., Robertson, A., Surgenor, A., Dokurno, P., Chen, I., Matassova, N., Smith, J., Pedder, C., Graham, C., Studeny, A., Lysiak-Auvity, G., Girard, A.-M., Gravé, F., Segal, D., Riffkin, C. D., Pomilio, G., Galbraith, L. C. A., Aubrey, B. J., Brennan, M. S., Herold, M. J., Chang, C., Guasconi, G., Cauquil, N., Melchiore, F., Guigal-Stephan, N., Lockhart, B., Colland, F., Hickman, J. A., Roberts, A. W., Huang, D. C. S., Wei, A. H., Strasser, A., Lessene, G., & Geneste, O.
- Affiliations
- Vernalis (R&D) Limited (United Kingdom) (GB)
- Institut de Recherches Internationales Servier (France) (FR)
- The University of Melbourne (AU)
- Monash University (AU)
- The Royal Melbourne Hospital (AU)
- The Alfred Hospital (AU)
- Corresponding author
- Geneste, Olivier
- ORCID
- Kotschy, András
- Murray, James
- Davidson, James
- Kelly, Gemma L.
- Moujalled, Donia M.
- Surgenor, Allan
- Dokurno, Pawel
- Chen, Ijen
- Matassova, Natalia
- Graham, Christopher
- Girard, Anne-Marie
- Segal, David
- Riffkin, Chris D.
- Galbraith, Laura C. A.
- Aubrey, Brandon J.
- Brennan, Margs S.
- Herold, Marco J.
- Chang, Catherine
- Melchiore, Fabien
- Colland, Frédéric
- Hickman, John A.
- Roberts, Andrew W.
- Huang, David C. S.
- Wei, Andrew H.
- Strasser, Andreas
- Venue
- Nature
- Published
- 2016-10
- Volume
- 538
- Issue
- 7626
- Pages
- 477-482
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2534349779
- Semantic Scholar
- 804d41f048a7386a3e6b3fcd1589511de3fabcd4
- Cited by
- 1,047
- References
- 52
- Citations by year
- 2026: 63 · 2025: 87 · 2024: 75 · 2023: 100 · 2022: 99 · 2021: 133 · 2020: 152 · 2019: 123 · 2018: 120 · 2017: 83 · 2016: 8
- FWCI
- 48.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- S63845, BH3-binding groove, apoptosis, mitochondrial apoptosis, multiple myeloma, leukemia, lymphoma, solid tumors, antitumour activity, drug safety, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Female, Humans, Leukemia, Lymphoma, Male, Models, Biological, Models, Molecular, Multiple Myeloma, Neoplasms, Pyrimidines, Thiophenes, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, bcl-2 Homologous Antagonist-Killer Protein, bcl-2-Associated X Protein, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
